MARKET

OTIC

OTIC

Otonomy Inc
NASDAQ
0.2807
+0.0137
+5.13%
Closed 16:00 10/04 EDT
OPEN
0.2802
PREV CLOSE
0.2670
HIGH
0.3060
LOW
0.2705
VOLUME
317.43K
TURNOVER
49.35K
52 WEEK HIGH
2.590
52 WEEK LOW
0.2400
MARKET CAP
16.00M
P/E (TTM)
-0.3589
1D
5D
1M
3M
1Y
5Y
BRIEF-Otonomy Inc - On September 14, 2022, Co Received Notice From Nasdaq That Co Is Not Been Compliance With The Minimum Bid Price Requirement
BRIEF-Otonomy Inc - On September 14, 2022, Co Received Notice From Nasdaq That Co Is Not Been Compliance With The Minimum Bid Price Requirement
Reuters · 09/16 21:10
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 08/22 12:25
Why AMC Entertainment Is Trading Lower By 33%; Here Are 31 Stocks Moving Premarket
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares rose 48.5% to $0.56 in pre-market trading. Kiromic Biopharma said the company has determined not to pursue, at this time, the contemplated public offering to which the registration statement relates.
Benzinga · 08/22 11:13
BRIEF-Otonomy Inc Says Plans To Reduce Its Workforce By About 55%
BRIEF-Otonomy Inc Says Plans To Reduce Its Workforce By About 55%
Reuters · 08/09 21:42
Otonomy cut to Neutral at H.C. Wainwright after setback for tinnitus candidate
H.C. Wainwright has downgraded the neurotology-focused Otonomy, Inc. (NASDAQ:O...
Seekingalpha · 08/02 19:20
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Benzinga · 08/01 22:41
U.S. Stocks Turn Negative; Dow Drops Over 100 Points
U.S. stocks turned lower toward the end of trading, with the Dow Jones falling more than 100 points on Monday.
Benzinga · 08/01 18:39
U.S. Stocks Turn Higher; Crude Oil Tumbles
U.S. stocks turned higher midway through trading, after recording gains in the previous session.
Benzinga · 08/01 16:21
More
About OTIC
Otonomy, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.

Webull offers kinds of Otonomy Inc stock information, including NASDAQ:OTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTIC stock methods without spending real money on the virtual paper trading platform.